Kythera Biopharmaceuticals Inc (KYTH) financial statements (2022 and earlier)

Company profile

Business Address 27200 WEST AGOURA ROAD
CALABASAS, CA 91301
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments99,661167,05879,311
Cash and cash equivalents29,226111,51879,311
Short-term investments70,43555,540 
Restricted cash and investments 5,0627,657
Prepaid expense and other current assets1,156621
Other undisclosed current assets1,498  
Total current assets:101,159173,27687,589
Noncurrent Assets
Property, plant and equipment1,84794275
Regulated entity, other noncurrent assets29,2307361,076
Restricted cash and investments  8,321
Other noncurrent assets420 
Prepaid expense and other noncurrent assets3737
Other undisclosed noncurrent assets(29,230)(736)(1,076)
Total noncurrent assets:2,2671318,633
TOTAL ASSETS:103,426173,40796,222
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11,6519,5339,187
Accounts payable4,6903,2282,152
Accrued liabilities2,1033,1914,862
Employee-related liabilities4,8583,1142,173
Debt5,4845,5261,160
Other liabilities637  
Other undisclosed current liabilities2,8572,5225,875
Total current liabilities:20,62917,58116,222
Noncurrent Liabilities
Long-term debt and lease obligation22,6615,9792,764
Long-term debt, excluding current maturities22,6615,9792,764
Liabilities, other than long-term debt69889
Deferred revenue and credits 89
Other liabilities698  
Other undisclosed noncurrent liabilities  8,321
Total noncurrent liabilities:23,3595,98711,094
Total liabilities:43,98823,56827,316
Stockholders' equity
Stockholders' equity attributable to parent59,438149,83968,906
Additional paid in capital367,329322,052189,212
Accumulated other comprehensive income (loss)(53)4 
Accumulated deficit(307,838)(172,217)(120,306)
Total stockholders' equity:59,438149,83968,906
TOTAL LIABILITIES AND EQUITY:103,426173,40796,222

Income statement (P&L) ($ in thousands)

12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)
  19,687
Cost of revenue
(Cost of Goods and Services Sold)
  (1,936)
Gross profit:  17,751
Operating expenses(131,652)(50,066)(53,689)
Operating loss:(131,652)(50,066)(35,938)
Nonoperating income
(Investment Income, Nonoperating)
260135 
Interest and debt expense(4,157)(1,980)(169)
Loss from continuing operations before income taxes:(135,549)(51,911)(36,107)
Income tax benefit 24,24014,913
Net loss:(135,549)(27,671)(21,194)
Other undisclosed net loss attributable to parent(72)(24,240)(15,605)
Net loss available to common stockholders, diluted:(135,621)(51,911)(36,799)

Comprehensive Income ($ in thousands)

12/31/2014
12/31/2013
12/31/2012
Net loss:(135,549)(27,671)(21,194)
Other comprehensive income (loss)(57)4 
Comprehensive loss:(135,606)(27,667)(21,194)
Other undisclosed comprehensive loss, net of tax, attributable to parent(72)(24,240)(15,605)
Comprehensive loss, net of tax, attributable to parent:(135,678)(51,907)(36,799)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: